

Assessment of the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia Disorder Control in Myopic Children DYMOND Study

NCT07390500

Status	RECRUITING
Phase	Phase 2
Sponsor	NovaSight
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (7)

- Aged 6-12 years
 - Diagnosed with myopia: cycloplegic spherical or spherical equivalent (SER) between -0.75D and -5.00D, astigmatism \leq -1.50D, anisometropia \leq 1.50D
 - Visual acuity 20/32 or better (age-appropriate testing) in both eyes
 - Interocular VA difference \leq 1.00 logMAR line
 - Subject in general good health and able, as per investigator decision, to comply with study visits and protocol procedures
- ... and 2 more (see full listing online)

Exclusion (6)

- Past or concurrent use of any other myopia treatment (e.g., atropine, orthokeratology, myopia control glasses/lenses)
 - Eye diseases or abnormality, developmental conditions, or past ocular surgeries or any other condition which could potentially affect refraction or AL progression according to the investigator's judgement
 - Current or prior history of manifest strabismus, amblyopia, or nystagmus
 - Subject cannot pass eye tracking calibration in at least 50% of cases, or cannot be tracked in at least 50% of the time during a screening eligibility test
 - Current or previous use of bifocal lenses, progressive-addition lenses, or multi-focal contact lenses
- ... and 1 more (see full listing online)

Locations (1 total)

Kaplan MC, Rehovot, Israel